Febuxostat for the Treatment of Chronic Tophaceous Gout in a Patient on Continuous Ambulatory Peritoneal Dialysis.
10.3904/kjm.2015.89.2.229
- Author:
Jeong Hee YUN
1
;
Hee Yeoun KIM
;
Dong Han KIM
;
Joon Seok OH
;
Seong Min KIM
;
Young Hun SIN
;
Joong Kyung KIM
Author Information
1. Department of Internal Medicine, Bong Seng Memorial Hospital, Busan, Korea. j-seok@hanmail.net
- Publication Type:Case Report
- Keywords:
Chronic kidney failure;
Tophi;
Febuxostat
- MeSH:
Allopurinol;
Arthritis, Gouty;
Gout*;
Humans;
Hyperuricemia;
Kidney Failure, Chronic;
Metabolism;
Peritoneal Dialysis;
Peritoneal Dialysis, Continuous Ambulatory*;
Renal Insufficiency, Chronic;
Uric Acid;
Xanthine Oxidase;
Febuxostat
- From:Korean Journal of Medicine
2015;89(2):229-232
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Hyperuricemic patients with gouty arthritis or tophi, a serum uric acid concentration of 8.0 mg/dL or higher, and complications should be treated with urate-lowering drugs. Conventionally, allopurinol is used to treat hyperuricemia and gout, but it is necessary to adjust the dosage according to the degree of renal impairment. Uncommonly, allopurinol may have severe or fatal side effects. The non-purine xanthine oxidase inhibitor febuxostat undergoes hepatic metabolism and may require less dose adjustment in association with renal function. It is considered to be an alternative treatment for hyperuricemic patients with chronic kidney disease. Our experience suggests that low-dose febuxostat is a promising alternative to allopurinol for the treatment of gouty arthritis or tophi in peritoneal dialysis patients.
